At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
Andecaliximab +1 moredrug
Likely dose
Andecaliximab 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 1 clinical trial evaluating Andecaliximab and Placebo to match Andecaliximab for Chronic Obstructive Pulmonary Disease. Completed, enrolled 11 participants across 5 sites.
Detailed Summary
The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartMar 2014
Primary CompletionOct 2014
TodayJul 2026
First PostedMar 4, 2014
Enrollment StartMar 11, 2014
Primary CompletionOct 27, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.3 years ago
Interventions
Andecaliximabdrug
400 mg andecaliximab administered intravenously
Placebo to match Andecaliximabdrug
Placebo to match andecaliximab administered intravenously